Kester Capital, a UK lower mid-market private equity specialist, has invested in MAP Patient Access, a specialist in market access consulting services to the pharmaceutical and biotech sectors.
The investment represents Kester’s fifth investment in the life sciences sector.
Headquartered in Cambridge, MAP is dedicated to accelerating patient access to ground-breaking medicines, devices, and diagnostics. It has a proven track record of helping its customers navigate increasingly complex healthcare reimbursement pathways, with particular expertise in rare and orphan diseases and cell and gene therapies. MAP’s integrated approach blends best-in-class consulting with membership including its proprietary digital platform, MAP Online, which provides market access intelligence to its customers.
This transaction with Kester will allow MAP to invest in broadening its service offering and expand into new territories. Kester and management will also target acquisitions to accelerate the growth of the MAP platform.
